Clinical Research Directory

Inclusion Criteria: * Pathological diagnosis confirmed metastatic solid tumors (breast cancer, sarcoma, and some thyroid cancers, etc.) that failed standard treatment or lacked standard treatment * Age: 75 ≥ age ≥ 18 years * ECOG score: 0 - 2 * 68Ga-CTR-FAPI PET/CT confirmed high expression of FAP in the tumor (more than 50% of the lesions with SUVmax ≥ 10) * The FAP immunohistochemical score of tumor cells is ≥ 2 (except for thyroid cancer) * There is at least one measurable lesion (RECIST 1.1) * Organ/marrow functions meet the specified thresholds, and there are no severe electrocardiogram abnormalities (QTcF ≤ 470ms) Exclusion Criteria: * There is brain metastasis or other central nervous system lesions. * The expected survival period is less than 6 months. * Within 4 weeks before administration, the patient has received chemotherapy, targeted therapy, immunotherapy, or other anti-tumor treatments or investigational drugs. * The patient has previously received other systemic radionuclide therapy (excluding 131I treatment for thyroid cancer). * There is uncontrolled pleural effusion, ascites, severe cardiovascular or cerebrovascular diseases, or infection.